Lonza Expands Bend Facility for Enhanced Clinical Bottling and Labeling
Lonza expands Bend, Oregon facility for faster clinical bottling, labeling, and early-phase trial support.
Global pharmaceutical, biotech, and nutraceutical partner Lonza has increased the capacity of its Bend, Oregon facility for clinical bottling and labelling. The new technology can identify faults in tablets and capsules, clean, fill, cap and seal, and label bottles for early-phase clinical studies. Lonza is able to expedite product delivery to clinical trial centres as a result.
The new bottling equipment, according to Matthew Ferguson, Senior Director, Product Development, Small Molecules, Lonza, will help clients who want to move their candidate route through phase I and II clinical trials and beyond more quickly. Clinical and commercial development as well as manufacturing are supported by Lonza's Drug Product Formulation and Development Services.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Altro da Pharma News
Tutti gli articoli →
Ab Science rivede i tempi dei trial dopo tre ispezioni GCP
Novo Nordisk Firma un Accordo da $2.6B con Hengrui per GLP-1 Orale
Discussion